Literature DB >> 6864524

Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.

R E Billings.   

Abstract

Phenytoin (DPH) is metabolized in isolated hepatocytes from male rats by hydroxylation to 5-(4-hydroxyphenyl)-5-phenylhydantoin, 5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin (dihydrodiol) and a catecholic metabolite, 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin, which is further metabolized by methylation of one of the phenolic hydroxyl groups. Isolated hepatocytes from female rats convert DPH to the initial metabolites, but only trace amounts of the catechol are formed. Similar results were obtained in vivo and with liver homogenate preparations. Incubation of possible precursor metabolites to the catechol indicate that the sex difference in catechol formation is due to differences in 5-(4-hydroxyphenyl)-5-phenylhydantoin hydroxylation rather than to differences in oxidation of the dihydrodiol metabolite. It is postulated that different isozymes of cytochrome P-450 catalyze the hydroxylation of DPH and its p-phenol metabolite because sex differences are observed only in the second hydroxylation step. Furthermore, the sex difference may be due to lower activity of one or more cytochrome P-450 isozymes in female rats than in male rats. These results may have important implications in the pharmacological activity and toxicity of DPH.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6864524

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability.

Authors:  Adnan A Kadi; Hany W Darwish; Mohamed W Attwa; Sawsan M Amer
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

2.  Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling.

Authors:  Hatem A Abdel-Aziz; Wagdy M Eldehna; Adam B Keeton; Gary A Piazza; Adnan A Kadi; Mohamed W Attwa; Ali S Abdelhameed; Mohamed I Attia
Journal:  Drug Des Devel Ther       Date:  2017-08-09       Impact factor: 4.162

3.  Development and validation of an HPLC-MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study.

Authors:  Haitham Alrabiah; Adnan A Kadi; Mohamed W Attwa; Gamal A E Mostafa
Journal:  Chem Cent J       Date:  2018-05-02       Impact factor: 4.215

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.